Neoplastic cells are a rare component in human glioblastoma microvasculature.
Microvascular proliferation is a key biological and diagnostic hallmark of human glioblastoma, one of the most aggressive forms of human cancer. It has recently been suggested that stem-like glioblastoma cells have the capacity to differentiate into functional endothelial cells, and that a significant proportion of the vascular lining in tumors has a neoplastic origin. In principle, this finding could significantly impact the efficacy and development of antiangiogenic therapies targeting the vasculature. While the potential of stem-like cancer cells to form endothelium in culture seems clear, in our clinical experience using a variety of molecular markers, neoplastic cells do not contribute significantly to the endothelial-lined vasculature of primary human glioblastoma. We sought to confirm this impression by analyzing vessels in glioblastoma previously examined using chromogenic in situ hybridization (CISH) for EGFR and immunohistochemistry for mutant IDH1. Vessels containing cells expressing these definitive neoplastic markers were identified in a small fraction of tumors, but only 10% of vessel profiles examined contained such cells and when identified these cells comprised less than 10% of the vascular cellularity in the cross section. Interestingly, these rare intravascular cells showing EGFR amplification by CISH or mutant IDH1 protein by immunohistochemistry were located in the middle or outer portions of vessel walls, but not amongst the morphologic boundaries of the endothelial lining. To more directly address the capacity of glioblastoma cells to contribute to the vascular endothelium, we performed double labeling (Immunofluorescence/FISH) for the endothelial marker CD34 and EGFR gene locus. This analysis did not identify EGFR amplified CD34+ endothelial cells within vascular linings, and further supports our observation that incorporation of glioblastoma cells into the tumor vessels is, at best, extremely rare of questionable clinical or therapeutic significance.
Department of Pathology, Division of Neuropathology, Johns Hopkins University, MD, USA. frodrig4@jhmi.edu
Fausto J
FJ
Rodriguez
Brent A
BA
Orr
Keith L
KL
Ligon
Charles G
CG
Eberhart
D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D001932:Brain Neoplasms / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002452:Cell Count; D004730:Endothelium, Vascular / Q000378:metabolism / Q000473:pathology; D066246:ErbB Receptors / Q000378:metabolism; D018773:Genes, erbB-1 / Q000502:physiology; D005909:Glioblastoma / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D055806:Microvessels / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000473:pathology*
D018952:Antigens, CD34; C512478:EGFR protein, human; D066246:ErbB Receptors